製薬業界のイノベーション<br>Leading Pharmaceutical Innovation : Trends and Drivers for Growth in the Pharmaceutical Industry (2004. XI, 178 p. w. 53 ill.)

製薬業界のイノベーション
Leading Pharmaceutical Innovation : Trends and Drivers for Growth in the Pharmaceutical Industry (2004. XI, 178 p. w. 53 ill.)

  • ただいまウェブストアではご注文を受け付けておりません。 ⇒古書を探す
  • 製本 Hardcover:ハードカバー版/ページ数 178 p.
  • 商品コード 9783540407171

基本説明

Illustrated with the case of the Swiss pharmaceutical industry.

Full Description


The pharmaceutical industry is in a dire situationmore drugs than 10 years ago, while costs have quadrupled in the meantime. Little advances have been made in innovation efficiency. Worse yet, drug development times are unacceptably long, possible drug development targets are waning, and national healthcare is tightening the cost squeeze. A predictable and efficient pipeline of drug candidates, coupled with a handful of blockbuster drugs, is considered the Holy Grail of pharmaceutical innovation. In this book, the authors develop a case for mastering pharmaceutical innovation focusing on three leading sources of future pharmaceutical competitiveness: new technologies and techniques, better pipeline management, and stronger integration of external innovation. Illustrated with plenty of real-life cases, this book tells you how to put the principles of leading pharmaceutical innovation into practice.

Table of Contents

Preface                                            v
Innovation as a Key Success Factor in the 1 (22)
Pharmaceutical Industry
The Productivity Paradox 1 (4)
The Blockbuster Imperative 5 (5)
Strategies for Growth 10 (3)
Do You Want to Be in This Industry? 13 (2)
Bargaining Power of Suppliers 15 (1)
Bargaining Power of Buyers 15 (1)
Risk of Entry from Potential Competitors 16 (1)
Threat of Substitute Products 17 (1)
Regulative Forces 17 (1)
Rivalry among Established Companies 18 (1)
Differentiation via Clinical Profiles 19 (1)
Entering the Market Quickly 20 (1)
Conclusions 21 (2)
Pharmaceutical Innovation: The Case of 23 (30)
Switzerland
Largest Economic Value-Added of GDP in 23 (2)
Switzerland
Stable Market Growth 25 (5)
Sound Productivity and Employment 30 (1)
Strong Support by Industry Associations 31 (2)
Highly Global Orientation 33 (1)
Complex Industry and Product 34 (5)
Classification
Fragmented Market Structure 39 (4)
Conjoined Financing Systems 43 (1)
Strict New Drug Registration 44 (6)
Accurate Price Regulation 50 (3)
The Science and Technology Challenge: How 53 (18)
to Find New Drugs
Rise of the Biotechnology Industry: 53 (5)
Boosting Innovation
High Throughput Screening: Fail Earlier, 58 (1)
Succeed Sooner
Combinatorial Chemistry: Cut Experimental 59 (1)
Cycle Times
Bioinformatics: More than 100 Gigabyte of 60 (2)
Data per Day
Proteomics: Profiting from the Human 62 (1)
Genome Project
Genomics: Towards Individualization and 63 (3)
Mass Customization
Pharmacogenomics: Create Tailor-made Drugs 66 (1)
Molecular Design: From Experimenting to 67 (1)
Analytic Design
Conclusions 68 (3)
The Pipeline Management Challenge: How to 71 (16)
Shape the Innovation-Flow
The Importance of Pipeline Management 71 (4)
The Complexity of Drug Discovery 75 (4)
The Different Phases of the R&D Process 79 (3)
The R&D Process at Hoffmann-La Roche 82 (3)
Conclusions 85 (2)
The Outsourcing and Internationalization 87 (30)
Challenge: How to Harness Outside Innovation
Impact of Outsourcing on the 87 (4)
Pharmaceutical Value Chain
Successful Commercialization of a 91 (6)
Breakthrough Technology
Trends and Drivers of Internationalization 97 (5)
R&D Internationalization of Swiss 102(4)
Pharmaceutical Companies
Locations of Pharmaceutical R&D Abroad 106(4)
Three Principal Problems of International 110(4)
R&D
Conclusions 114(3)
Management Answers to Pharmaceutical R&D 117(22)
Challenges
Managing the Research-to-Development 117(2)
Handover
Managing Human Resources 119(2)
Managing Projects and the Portfolio 121(3)
Managing Outsourcing Activities 124(3)
Managing Intellectual Property Rights 127(4)
Managing R&D Strategy at Schering 131(2)
Managing Virtual Project Management Pools 133(2)
at Roche
Managing Uncertainty at Roche 135(1)
Managing Know-how Transfer at Kao 136(1)
Conclusions 137(2)
Future Directions and Trends 139(4)
Appendices 143(16)
Case: R&D Management at Novartis 143(8)
Case: R&D Management at Roche 151(8)
Bibliography 159(6)
Index 165(6)
Glossary 171(6)
Authors 177